Central areolar choroidal dystrophy is a rare inherited eye condition that affects central vision. People with this condition often notice blurred or distorted central sight and difficulty reading or recognizing faces. Symptoms usually begin in mid-adulthood and tend to worsen slowly over years. CACD does not affect life expectancy, but it can lead to significant vision loss. Treatment focuses on vision rehabilitation, low-vision aids, and monitoring, and genetic testing can sometimes clarify why CACD appears in families.
Overview
Central areolar choroidal dystrophySymptoms
Central areolar choroidal dystrophy causes gradually worsening central vision, making reading, recognizing faces, and seeing detail hard. Early symptoms include blurred or wavy print, faded colors, glare sensitivity, and a small central dark spot; side vision usually stays intact.
Outlook and prognosis
Many living with central areolar choroidal dystrophy notice slow, central vision loss over decades, with side vision typically spared. Reading and recognizing faces can become harder, but low-vision tools and tailored lighting help. Regular monitoring guides timing for aids and support.
Causes and risk factors
Central areolar choroidal dystrophy usually results from a single gene change, typically passed down when one parent carries it. Family history strongly raises risk; new mutations can occur. Age and cumulative light exposure may influence how quickly it worsens.
Genetic influences
Genetics play a central role in central areolar choroidal dystrophy, with many cases inherited in families. Variants in genes like PRPH2 are common, though other genes can be involved. Genetic testing can confirm the cause, guide prognosis, and inform family planning.
Diagnosis
Doctors suspect central areolar choroidal dystrophy from characteristic macular changes and vision loss. Confirmation typically uses retinal imaging (OCT, autofluorescence), visual testing, and sometimes genetic tests. Genetic diagnosis of central areolar choroidal dystrophy can clarify subtype and family risk.
Treatment and drugs
Treatment for central areolar choroidal dystrophy focuses on protecting remaining vision and maximizing day‑to‑day function. Care may include low‑vision aids, bright task lighting, stopping smoking, nutrition support, and regular eye checks. Clinical trials are exploring gene‑directed and regenerative therapies.
Symptoms
Central areolar choroidal dystrophy (CACD) mainly affects central vision, making detailed tasks harder over time. You might notice small changes at first—letters look less crisp, colors seem duller, or a faint blur sits in the center of your view. Early features of central areolar choroidal dystrophy often involve reading and face recognition, especially in bright light or glare. These changes can progress slowly, and some days may feel better than others.
A faint gray or dark patch may appear where you focus, making letters or faces look incomplete. It can slowly enlarge with central areolar choroidal dystrophy.
Fine print can look faded, broken, or like pieces are missing, so words take longer to make sense. Many people find they need brighter, even lighting.
Recognizing faces, especially in crowds or on TV, can become harder. You may start relying more on voice, hairstyle, or movement to identify people.
Straight edges on doorframes or lines on a page may look wavy or bent. In central areolar choroidal dystrophy, this distortion often sits right where you try to focus.
How people usually first notice Central areolar choroidal dystrophy?
Many people first notice central areolar choroidal dystrophy when straight lines look wavy or a small blurred or dim spot appears right in the center of vision, making reading or recognizing faces harder, especially in low light. Eye doctors are often alerted by these changes and confirm them with tests that show thinning in the central retina (the macula), sometimes after a family member mentions similar vision problems since this condition can run in families. If it appears earlier, teens or young adults may be flagged during routine eye exams for subtle central vision changes before symptoms feel obvious, which is why reporting new central blurriness promptly matters when discussing the first signs of central areolar choroidal dystrophy.
Types of Central areolar choroidal dystrophy
Central areolar choroidal dystrophy (CACD) affects central vision used for reading, faces, and fine detail, while side vision is usually spared. Symptoms don’t always look the same for everyone. Clinicians often describe them in these categories: early changes, intermediate decline, and advanced central vision loss, which reflect how the macula and supporting layer thin over time. When people search for types of CACD, they often mean these stages, which can progress at different speeds even within the same family.
Early/stage 1
Subtle changes in the central retina may show up on an eye exam before day‑to‑day problems are obvious. You might notice mild blur or need more light for reading, especially in dim rooms. Color contrast can feel slightly washed out.
Intermediate/stage 2
Blurry or wavy central vision becomes more noticeable, and small print can be hard to read even with new glasses. People may need brighter lighting and larger text, and colors can look less vivid. Night or low‑light tasks often feel harder.
Advanced/stage 3–4
A well‑defined central blind spot can form, making reading and face recognition difficult while side vision stays intact. People often rely on peripheral vision and magnifiers or digital aids for detail work. The exact pace from stage to stage can vary.
What genetics can tell you about symptoms
Certain variations in the PRPH2 gene can damage the retina’s central support layer, leading to slowly worsening blurry vision, trouble reading, and difficulty seeing fine details. Some people also notice increased light sensitivity and central blind spots as the macula thins over time.
Causes and risk factors
Central areolar choroidal dystrophy is mainly caused by a change in a gene called PRPH2, most often inherited in an autosomal dominant way.
A parent with the gene change has a 50% chance to pass it to each child, and sometimes a new change appears with no family history.
The main risk factors for central areolar choroidal dystrophy are carrying this gene change and having a close relative who has it.
Age can influence when symptoms start, and lifestyle or environmental exposures may affect severity even though evidence is limited.
Risk can vary widely from person to person.
Environmental and biological risk factors
Central areolar choroidal dystrophy is mainly driven by internal eye biology, and few environmental or biological exposures have been confirmed to change the chance it occurs. Researchers are still exploring how outside influences interact with our inner biology. Based on current evidence, common environmental exposures, infections, or injuries have not been shown to trigger this condition. Below are environmental and biological risk factors for Central areolar choroidal dystrophy that are currently known—or notably not supported.
There is no clear evidence that exposure to heavy metals, organic solvents, or common air pollutants increases the likelihood of Central areolar choroidal dystrophy. Studies have not identified consistent environmental triggers for this condition. Routine community exposure levels have not been linked to higher risk.
Sunlight and other sources of ultraviolet light have not been shown to cause this condition. No reliable link has been found between UV exposure and the chance it occurs.
Prior eye trauma does not appear to increase the chance of developing Central areolar choroidal dystrophy. The condition typically arises without any triggering injury.
Men and women appear similarly affected. No sex-specific biological factors have been confirmed to raise or lower risk.
Genetic risk factors
Central areolar choroidal dystrophy often runs in families because of variants in the PRPH2 gene, which helps the eye’s light‑sensing cells keep their structure. Most affected families show autosomal dominant inheritance, meaning one altered copy can be enough to raise risk. Carrying a genetic change doesn’t guarantee the condition will appear. Genetic clues can be present years before the early symptoms of central areolar choroidal dystrophy, so understanding your family pattern can guide testing.
PRPH2 gene variants: Changes in PRPH2 (also known as RDS) are the most established genetic cause of central areolar choroidal dystrophy. The gene supports the outer segments of photoreceptor cells; faults can gradually damage the central retina. Different variants can be linked to different ages of onset and severity.
Dominant inheritance: If a parent carries a disease‑causing PRPH2 variant, each child has a 50% chance of inheriting it. Features often appear in adulthood, so a family history may not be obvious in younger generations. People with the same risk factor can have very different experiences.
Variable expressivity: The same PRPH2 change can affect people differently, even within one family. Some may have subtle macular changes on exam, while others develop the classic central areolar atrophy.
Age‑related penetrance: Signs of central areolar choroidal dystrophy often emerge in mid‑ to late‑adulthood. Someone who carries a causal variant may have a normal eye exam for years.
Incomplete penetrance: Not everyone who inherits a PRPH2 variant will develop noticeable symptoms. This can make the condition seem to skip generations.
Rare other genes: A small number of families show similar macular findings due to changes in other, less common genes. In some cases, genetic testing can give a clearer picture of your personal risk.
De novo variants: Occasionally, a PRPH2 change appears for the first time in someone with no family history. In that situation, parents may test negative, and siblings usually have a low chance of having the same variant.
Genetic counseling: A genetics professional can explain inheritance, discuss testing options, and outline what results may mean for relatives. Knowledge can help families feel more prepared and less anxious.
Lifestyle risk factors
Lifestyle habits do not cause Central areolar choroidal dystrophy, but they can influence symptom burden and possibly the pace of vision decline. Practical choices around smoking, light exposure, diet, and cardiovascular health may help protect remaining macular function. In this context, lifestyle risk factors for Central areolar choroidal dystrophy are targets for change, not reasons for blame. Small, consistent adjustments can improve daily visual comfort and long-term eye health.
Tobacco smoke increases oxidative stress in the macula and may hasten damage to vulnerable photoreceptors in CACD. Quitting can help preserve residual central vision and reduce the risk of faster atrophic change.
Intense sunlight and glare can worsen photophobia and add phototoxic stress to macular cells already at risk in CACD. Wearing UV/blue‑filtering sunglasses and a brimmed hat can lessen symptoms and may limit cumulative light-related damage.
Eating foods rich in lutein, zeaxanthin, and omega‑3s may bolster macular pigment and support retinal resilience in CACD. This can improve contrast and glare tolerance, though evidence for slowing disease is limited.
Moderate aerobic exercise supports cardiovascular and choroidal blood flow that nourishes the macula. Consistent activity may help maintain visual function in CACD and supports balance and safety during vision changes.
Risk prevention
Central areolar choroidal dystrophy is inherited, so there’s no way to stop it entirely, but you can protect eye health and lower the impact over time. Even if you can’t remove all risks, prevention can reduce their impact. The focus is on regular monitoring, reducing strain and light damage, and planning early for vision changes. Support from eye specialists, primary care, and family can make these steps easier to follow.
See an eye doctor regularly for dilated exams and retinal imaging to spot changes early. Ask about the early symptoms of central areolar choroidal dystrophy and when to check in sooner. Early detection helps tailor monitoring and support.
Wear UV400 sunglasses and a brimmed hat outdoors to cut harmful light and glare. This can reduce light sensitivity and potential light-related stress on the macula in CACD. Wraparound frames can help in bright or reflective settings.
If you smoke, stopping can lower oxidative stress that harms retinal cells. Avoid secondhand smoke as well. Ask your doctor about medications or counseling that make quitting more manageable.
Keep blood pressure, cholesterol, and blood sugar in a healthy range. Good circulation supports the retina’s oxygen needs. Work with your primary care team on targets and follow-up.
Transmission
Central areolar choroidal dystrophy (CACD) is not contagious—you can’t catch it from someone or pass it through everyday contact. It most often runs in families in an autosomal dominant pattern, meaning a change in just one copy of a gene is enough to cause the condition. If a parent has CACD, each child has a 50% chance of inheriting the gene change and potentially developing symptoms, though severity and age of onset can vary within the same family. Less commonly, CACD can arise from a new genetic change in the child, with no prior family history. If you’re wondering how central areolar choroidal dystrophy is inherited, a genetics professional can review your family history, discuss testing, and explain risks for relatives.
When to test your genes
Central areolar choroidal dystrophy is genetic, so consider testing if you have central vision loss, a strong family history, or early subtle changes on eye exams. Testing helps confirm the diagnosis, guide monitoring, and inform family planning. If you’re unsure, start with a retinal specialist or genetic counselor to discuss benefits and limits.
Diagnosis
Central areolar choroidal dystrophy is often recognized by a characteristic pattern of central retinal changes and confirmed with eye imaging and, when helpful, genetic tests. Many notice slowly worsening central vision in mid-adulthood while side vision stays fairly clear, which can make reading or recognizing faces harder. Doctors usually begin with a detailed eye exam and history, then use imaging to map the affected area. A genetic diagnosis of central areolar choroidal dystrophy may be offered if your exam and scans fit the pattern or if others in your family are affected.
The ophthalmologist looks closely at the macula for a well-defined area of thinning or atrophy while the outer retina often looks normal. This pattern helps suggest central areolar choroidal dystrophy over more common causes of central vision loss.
Standard eye charts measure how clearly you see letters in the center of your vision. An Amsler grid may reveal waviness or a small central blind spot that aligns with everyday reading or face-recognition difficulties.
This noninvasive scan shows cross-sections of the retina, highlighting thinning of the light-sensing layers in the center. In central areolar choroidal dystrophy, it often shows loss of the photoreceptor and support layers in the macula, which helps track change over time.
Imaging maps the retina’s natural glow to show stressed or missing support cells. Central areolar choroidal dystrophy typically shows a dark central area with a brighter ring around it, which can make the diagnosis more specific.
Stages of Central areolar choroidal dystrophy
In central areolar choroidal dystrophy, vision changes usually progress in clear stages focused on the macula. Early and accurate diagnosis helps you plan ahead with confidence. Early symptoms of central areolar choroidal dystrophy often include mild central blur and trouble with small print, then gradually move toward more noticeable central vision loss.
Stage 1
Early changes: Vision may be normal or slightly blurry when reading or in dim light. An eye exam may show tiny, patchy changes in the center of the retina.
Stage 2
Growing mottling: Reading slows and contrast feels worse, especially at dusk or indoors. Doctors see a wider area of mottled tissue in the macula on imaging.
Stage 3
Central atrophy: A clear patch of wear develops in the macula, sometimes sparing the very center at first. Central vision declines, and brighter light and larger print are often needed.
Stage 4
Center involved: The wear reaches the very center, causing marked central vision loss while side vision typically remains. Recognizing faces and reading standard print become difficult.
Outlook and prognosis
Looking ahead can feel daunting, but most people with central areolar choroidal dystrophy (CACD) notice very gradual changes over many years. Many people ask, “What does this mean for my future?”, and the short answer is that CACD mainly affects central vision used for reading, driving, and recognizing faces, while side vision usually stays intact. Early symptoms of central areolar choroidal dystrophy can include needing brighter light, faded contrast, or a blurred spot in the middle; over time the central patch of vision may widen, making detailed tasks harder. Everyone’s journey looks a little different. Some people experience slow, stepwise changes, while others notice a more steady decline, which can depend on the gene involved and age at onset.
Understanding the prognosis can guide planning and help you time updates to glasses, lighting, and low-vision tools. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle. Most people with CACD do not lose all vision; peripheral vision generally remains, which supports getting around, socializing, and many daily activities. CACD itself is not life-shortening, and mortality is not increased by the eye condition. That said, vision loss can raise fall risk and limit independence, so addressing home safety, mobility training, and mental health can make a real difference in quality of life.
When thinking about the future, it helps to know that new assistive tech—like high-contrast e-readers, magnification apps, and orientation training—can keep work and hobbies possible for longer. With ongoing care, many people maintain strong independence, especially when they adapt lighting, use contrast cues in the kitchen, and plan travel routes that minimize glare or night driving. Talk with your doctor about what your personal outlook might look like. Genetic testing can sometimes provide more insight into prognosis, because some gene changes are linked to earlier or later progression, and this information can inform monitoring and family planning. Keep regular appointments—small adjustments can improve long-term health.
Long-term effects
Central areolar choroidal dystrophy typically brings a slow, progressive loss of sharp central vision over many years. Long-term effects vary widely, and the pace can differ even among relatives in the same family. Peripheral (side) vision usually remains, so moving around familiar spaces often stays possible even when reading becomes hard. Early symptoms of central areolar choroidal dystrophy may include mild blur when reading fine print, which can gradually shift to larger gaps in central vision.
Fine detail fades first, often making reading and recognizing faces progressively harder. Many eventually meet criteria for legal blindness, though complete blindness is uncommon.
Peripheral vision generally remains intact. This can help with navigating hallways and familiar routes even as central detail declines.
A central blind spot may appear and slowly widen. Over time, it can block words on a page or parts of a person’s face.
Colors can look washed out or less distinct over the years. Subtle shades, especially reds and greens, may become harder to tell apart.
How is it to live with Central areolar choroidal dystrophy?
Living with central areolar choroidal dystrophy often means a slow, frustrating loss of sharp central vision while side (peripheral) vision stays intact, so reading fine print, recognizing faces, and tasks like threading a needle or spotting a bus number can become challenging. Many adapt with high-contrast settings, larger fonts, strong lighting, magnifiers, and text-to-speech tools, and some adjust careers or driving habits depending on local regulations and safety. Day to day, this can add extra planning and fatigue, and it can affect partners, family, and coworkers who may share more visual tasks or help with transportation, but clear communication and practical support usually make routines smoother. People with this condition often find low-vision rehabilitation and peer support helpful to stay independent and confident.
Treatment and drugs
Central areolar choroidal dystrophy is managed by protecting remaining vision, treating related eye issues, and supporting day-to-day function, since no approved therapy can reverse the retinal damage yet. You might picture this as a team effort between you and your doctor, with regular eye exams, sunglasses with 100% UV/HEV protection, smoking cessation, and control of blood pressure and cholesterol to protect retinal health. Low-vision rehabilitation is central: customized magnification, high-contrast lighting, large-print or audio tools, and electronic aids can help with reading, work, and driving decisions; many also benefit from orientation and mobility training. Although living with central areolar choroidal dystrophy can feel overwhelming, supportive care can make a real difference in how you feel day to day. There are no proven drugs or supplements for this condition; your doctor may discuss clinical trials (including gene- or cell-based research), and it’s wise to ask whether you’re a candidate and how to safely participate.
Non-drug treatment
Central areolar choroidal dystrophy can make reading, driving, and detail work harder, especially in bright or low light. If you’re noticing early symptoms of central areolar choroidal dystrophy, practical strategies can help you protect independence at home, work, and on the go. Non-drug treatments often lay the foundation for staying active and safe while your eye team tracks changes. The goal is better day-to-day function, not just sharper letters on a chart.
A low-vision specialist teaches skills and tools to make the most of your remaining sight. Training is tailored to your goals, like reading mail, cooking, or using public transport.
Handheld magnifiers, stand magnifiers, and digital video magnifiers enlarge text and fine detail. Many people combine optical magnifiers for quick tasks with electronic devices for longer reading.
Brighter, even lighting and high-contrast materials can make print and tasks easier to see. Position lights to avoid glare and use bold, dark pens on white paper.
Filter lenses or wraparound sunglasses can cut glare and improve comfort outdoors and under harsh indoor lighting. Your provider can help you test tints to find the most helpful color and density.
Your genes may have an impact on how drugs work for you
Some medicines for people with central areolar choroidal dystrophy can work differently based on genes that affect drug breakdown and transport. Pharmacogenetic testing may guide dosing or drug choice, aiming for better benefit and fewer side effects.
Pharmacological treatments
There’s no approved drug that stops or reverses central areolar choroidal dystrophy, so care focuses on treating complications like abnormal blood vessels under the retina and supporting vision. Anti-VEGF eye injections used for “wet” macular disease are sometimes used if those problem vessels develop. Vitamins marketed for macular health haven’t been proven to slow central areolar choroidal dystrophy and should be discussed with your eye specialist. Not everyone responds to the same medication in the same way.
This anti-VEGF medicine can help shrink abnormal vessels if they form beneath the macula in central areolar choroidal dystrophy. It’s given by injection into the eye at intervals your retina specialist sets.
This anti-VEGF drug can be used similarly to ranibizumab when leakage or bleeding from new vessels threatens central vision. Many start with monthly injections, then extend the spacing if the eye stays quiet.
This anti-VEGF option is often used off-label because it’s more affordable and can control choroidal neovascularization in central areolar choroidal dystrophy. Ask your doctor why a specific drug was recommended for you.
Photodynamic therapy uses an intravenous drug (verteporfin) activated by a targeted light to seal leaky vessels in select cases. It may be considered when anti-VEGF injections aren’t suitable or response is limited.
Genetic influences
Genetics plays a central role in how and when this macular condition appears in families. In most families with Central areolar choroidal dystrophy (CACD), a single DNA change—often in a gene called PRPH2—is inherited in an autosomal dominant way, meaning one altered copy can cause disease and each child has about a 50% chance of inheriting it. Family history is one of the strongest clues to a genetic influence. Still, the condition can look different from one relative to another; age at onset and the pace of central vision loss can vary even when the same gene change is shared. Genetic testing for Central areolar choroidal dystrophy can confirm the diagnosis, clarify who in the family is at risk, and guide counseling on future pregnancies. A genetics professional can also help rule out related macular dystrophies that can mimic CACD and explain what results mean for you and your relatives.
Is Central areolar choroidal dystrophy genetic?
Genetics play a central role in central areolar choroidal dystrophy, with many cases inherited in families. Variants in genes like PRPH2 are common, though other genes can be involved. Genetic testing can confirm the cause, guide prognosis, and inform family planning.
Pharmacogenetics—how genetics influence drug effects
Because Central areolar choroidal dystrophy is inherited, the exact gene change can shape care plans even when medicines are limited. Right now, there are no approved drugs that change the course of Central areolar choroidal dystrophy; treatment is mainly supportive, so genetics mostly guides diagnosis, prognosis, and whether you might qualify for research. Identifying the causative gene—commonly in PRPH2—can prevent mislabeling it as inflammation or age-related macular disease and helps set realistic expectations for how vision may change over time. As gene and cell therapies evolve, matching a therapy to the specific variant will likely matter, and having genetic testing for Central areolar choroidal dystrophy documented can help with trial eligibility. For medicines used around the condition—such as drops for eye comfort or treatments for rare complications—general drug–gene interactions may influence dosing and side effects, but these results are separate from the gene that causes the dystrophy. Ask your doctor if pharmacogenetic testing could help clarify your subtype or connect you with research options.
Interactions with other conditions
For people living with Central areolar choroidal dystrophy, other eye or health conditions can change how vision behaves day to day. Doctors call it a “comorbidity” when two conditions occur together, and this can make it harder to sort out which problem is causing new changes. Central areolar choroidal dystrophy can look similar to age-related macular degeneration, and in some older adults the two may occur at the same time, making progression harder to judge and reading vision more fragile. Diabetes that affects the retina or long-standing high blood pressure can add swelling or small bleeds, which may further blur central sight and complicate treatment choices. Glaucoma can narrow side vision and cataracts can dim and cloud images, so together with Central areolar choroidal dystrophy they can mask early symptoms of Central areolar choroidal dystrophy and make everyday tasks—like recognizing faces or seeing street signs—more challenging. Because some families with Central areolar choroidal dystrophy also show related macular patterns tied to the same gene change, sharing your family eye history with your care team can help anticipate overlapping risks and coordinate follow-up.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns of vision changes that seemed to run through generations—relatives who read with more light, held books closer, or stopped driving at dusk. These everyday clues, shared quietly at kitchen tables, hinted at what we now call central areolar choroidal dystrophy, a condition that gradually wears down the center of sight used for reading and fine detail.
Throughout history, people described central blurring more than side vision loss, often assuming it was simply “bad eyesight” or the normal toll of aging. Early doctors recorded cases of adults who could navigate a room yet struggled to recognize faces across it. Those notes captured key features: a slow, central fading; relatively stable side vision; and multiple affected family members. As careful drawings gave way to retinal photographs in the 20th century, the same pattern emerged—an island of thinning at the center of the retina, with the surrounding tissue looking surprisingly intact.
First described in the medical literature as a distinct form of central retinal degeneration, it was separated from other causes of macular damage by its steady pace and the way it often appeared in midlife. Over time, descriptions became sharper as doctors learned to tell it apart from age-related macular degeneration, inherited macular dystrophies, and conditions linked to inflammation or toxins. The shared thread was the slow, progressive loss of central detail with preservation of peripheral vision, a feature that helped people keep moving around independently even as reading grew harder.
In recent decades, knowledge has built on a long tradition of observation. Imaging tools such as optical coherence tomography allowed clinicians to see layers of the retina and choroid in cross-section, confirming that the damage starts at the center and expands outward. These scans made it possible to measure change over time and to map the “areolar” zone—an area of thinning that matches people’s day-to-day experience of a small central blind spot.
Advances in genetics clarified why central areolar choroidal dystrophy clusters in families. Researchers linked many cases to changes in genes that help the eye handle everyday wear and tear in the light-sensing cells and their support tissues. This explained why early symptoms of central areolar choroidal dystrophy often appear after years of normal sight, and why the condition’s course can vary within and across families.
Looking back helps explain today’s approach: careful family history, detailed eye imaging, and, when appropriate, genetic testing to confirm the diagnosis and guide counseling. Not every early description was complete, yet together they built the foundation of today’s knowledge, turning family stories into a clearer picture of how this condition develops and why it behaves the way it does.